This company is no longer active
PhaseBio Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 0/6
Insufficient data to determine the health of PhaseBio Pharmaceuticals
Key information
n/a
Debt to equity ratio
n/a
Debt
| Interest coverage ratio | n/a |
| Cash | n/a |
| Equity | n/a |
| Total liabilities | n/a |
| Total assets | n/a |
Recent financial health updates
Recent updates
PhaseBio Pharmaceuticals GAAP EPS of -$0.34 misses by $0.03, revenue of $0.21M misses by $0.29M
Aug 12PhaseBio Pharmaceuticals (NASDAQ:PHAS) Has Debt But No Earnings; Should You Worry?
Aug 10
PhaseBio shares surge after inking exclusive license agreement for bentracimab
Jun 17What Kind Of Shareholders Hold The Majority In PhaseBio Pharmaceuticals, Inc.'s (NASDAQ:PHAS) Shares?
Mar 04If You Had Bought PhaseBio Pharmaceuticals' (NASDAQ:PHAS) Shares A Year Ago You Would Be Down 28%
Jan 08PhaseBio Pharmaceuticals EPS misses by $0.15
Nov 12Financial Position Analysis
Short Term Liabilities: Insufficient data to determine if PHAS.Q's short term assets cover its short term liabilities.
Long Term Liabilities: Insufficient data to determine if PHAS.Q's short term assets cover its long term liabilities.
Debt to Equity History and Analysis
Debt Level: Insufficient data to calculate PHAS.Q's net debt to equity ratio to determine if it is satisfactory.
Reducing Debt: Insufficient data to determine if PHAS.Q's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: Insufficient data to determine if PHAS.Q's debt is well covered by operating cash flow.
Interest Coverage: Insufficient data to determine if PHAS.Q's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/12 22:59 |
| End of Day Share Price | 2024/09/12 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PhaseBio Pharmaceuticals, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew Fein | H.C. Wainwright & Co. |
| Chad Messer | Needham & Company |
| Annabel Samimy | Stifel, Equities Research |